Jeff Evans has been editor of Rheumatology News/MDedge Rheumatology and the EULAR Congress News since 2013. He started at Frontline Medical Communications in 2001 and was a reporter for 8 years before serving as editor of Clinical Neurology News and World Neurology, and briefly as editor of GI & Hepatology News. He graduated cum laude from Cornell University (New York) with a BA in biological sciences, concentrating in neurobiology and behavior.
News
Fludarabine added to interferon hints at benefits for breakthrough MS
In a pilot study, relapsing-remitting multiple sclerosis patients who experienced breakthrough disease required fewer acute corticosteroids during...
News
Glatiramer acetate didn’t affect birth outcomes in women with multiple sclerosis
Key clinical point: Glatiramer acetate is not associated with adverse maternal or neonatal outcomes, but nonuse of any disease-modifying therapy...
News
FDA rejects antisense oligonucleotide drug for Duchenne muscular dystrophy
The Food and Drug Administration has decided against approving the exon 51–skipping antisense oligonucleotide drug drisapersen for forms of...
News
Study bolsters argument for sodium channel role in MS cerebellar dysfunction
Key clinical point: New evidence further supports previous evidence that Nav1.8 channelopathy is involved in the pathophysiology of cerebellar...
News
Anti-SPAG16 antibodies could be prognostic marker in primary progressive MS
Key clinical point: The presence of anti-SPAG16 antibodies could be a novel prognostic biomarker in PPMS, but further follow-up is required. Major...
News
T-cell biomarker not viable for detecting PML risk with natalizumab
Key clinical point: Measuring %CD62L does not appear to be a viable method for stratifying PML risk in natalizumab-treated MS patients. Major...
News
Rheumatology trends, research, concerns highlighted for 2016
The coming year in rheumatology brings with it a variety of trends and concerns about how rheumatologists can chart the best course for their...
News
Lateral wedge insoles provide minimal biomechanical help in knee OA
Key clinical point: Make sure that patients with medial knee OA have an appropriate biomechanical phenotype to use lateral wedge insoles. Major...
News
Pseudoatrophy with interferon beta-1a may warrant MRI delay in MS patients
Key clinical point: Initial treatment of patients with relapsing-remitting multiple sclerosis with subcutaneous interferon beta-1a may cause a...
Video
VIDEO: Trial points to using non-TNF biologic when first anti-TNF drug fails
Rheumatoid arthritis patients who did not respond to an initial tumor necrosis factor inhibitor had a higher rate of good or moderate response...